Objective
The incidence rate of Respiratory Compromise (RC) in hospital settings is 7% in intermediate/general care ward patients (107 million patients) and 30% in step-down postoperative patients (197 Million patients), at an average cost of €16,500 per event. It will cost the EU €31Bn by 2019. PMD’s technology will lead to a 20% reduction in the average patient length of stay, a 10% reduction in unplanned intensive care admissions, and a 5% reduction in liabilities from patient mortality by enabling early intervention of Respiratory Compromise (RC). This will be achieved by enabling the continuous and accurate monitoring of general ward patients respiratory rate (70% of the total patient population). The business opportunity is PMD Solutions (PMD), with its unique respiratory monitoring platform technology and its premier TRL7 CE marked product RespiraSense - the world’s first continuous respiratory rate monitor that is highly differentiated due to its ability to reject non-breathing artifact. This proposal, through the undertaking of clinical investigations, product optimisation, new product development and sales and marketing, will enable PMD to capture 0.4% of the market and sustain a 400% annual growth rate by 2020. It will lead to the generation of >€60M with sales across 3 continents including Europe, America and Asia and to grow the team from 10 to 21 within 3 years. PMD currently has 1 agreement with an Irish distributor and 7 Memorandum of Understanding (MoU) with other distributors across Europe with a further 25 other prospects. PMD is also in negotiations with the VP of marketing at each of the top 2 US (Welch Allyn, GE Medical) and the top Asian (Mindray) multinational patient monitoring companies. Globally hospital’s will save €775M over the next 3 years through their adoption of continuous monitoring of respiratory rate (RR). The unique technology platform has been validated on over 120 patients across 5 clinical areas in 5 hospitals, across 5 countries.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences nursing
- social sciences sociology demography mortality
- social sciences economics and business economics production economics productivity
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering sensors
- medical and health sciences clinical medicine cardiology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
T12T922 CORK
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.